Can PLIA Reduce Early Post-operative Pain After PAO Surgery?
Launched by MICHAEL C WILLEY · Jul 19, 2024
Trial Information
Current as of June 26, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is studying a treatment called peri-incisional local infiltrative anesthesia (PLIA) to see if it can help reduce pain after a specific hip surgery called periacetabular osteotomy (PAO). The researchers want to find out if using PLIA makes a difference in how much pain patients feel after surgery, how much pain medication they need, and if the timing of when PLIA is given affects these outcomes. Participants in the trial will be divided into three groups: one that doesn’t receive PLIA, one that gets it after their incision is closed, and another that receives it throughout the surgery.
To be eligible for this trial, participants should be between 13 and 50 years old and have been diagnosed with hip dysplasia, which is a condition that affects the hip joint. They must also be planning to have PAO surgery at the University of Iowa Hospital and Clinics. People who are pregnant, breastfeeding, or unable to provide consent, as well as those with certain allergies or medical conditions, will not be able to join. Participants can expect to fill out some surveys about their health and pain levels, while the research team will gather additional information from their medical records. This study is currently recruiting patients, and it aims to improve pain management for those undergoing this type of surgery.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Adolescent or young adult diagnosed with hip dysplasia indicated for PAO at University of Iowa Hospital and Clinics.
- Exclusion Criteria:
- • Unable to provide informed consent.
- • Pregnant or breast-feeding individuals
- • Prisoner or ward of the state
- • Allergy or medical contradiction to any of the study medications
- • Patients undergoing femoral osteotomy or surgical hip dislocation with PAO will be excluded
About Michael C Willey
Michael C. Willey is a dedicated clinical trial sponsor committed to advancing medical research and improving patient outcomes through innovative and rigorous clinical studies. With a focus on enhancing therapeutic interventions across various therapeutic areas, Mr. Willey brings extensive expertise in trial design, regulatory compliance, and patient safety. His leadership emphasizes collaboration with healthcare professionals, research institutions, and regulatory bodies to ensure the successful execution of trials that adhere to the highest ethical and scientific standards. Through his work, Michael C. Willey aims to contribute significantly to the development of cutting-edge treatments that address unmet medical needs.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Iowa City, Iowa, United States
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported